** Shares of Divi's Laboratories DIVI.NS rise as much as
1.38% to 2,829.95 rupees in a weak market
** DIVI among top gainers in Nifty 50 .NSEI and Nifty
Pharma .NIPHARMA , which are down 1.06% and 0.41%, respectively
** Easing cost pressures indicate improved profitability
going forward, says Motilal Oswal after meeting with co's
management
** Relaxation in power, fuel and freight cost as well as
expected demand recovery for API products to aid further growth,
says brokerage
** Adds DIVI could post 15% annual average earnings growth
over FY23-FY25
** Brokerage, however, finds valuations expensive and
maintains "neutral" rating on DIVI
** Four of 22 analysts tracking DIVI maintain "buy", nine
suggest "sell" and nine recommend "hold"; median PT is 2,820
rupees
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463))